Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

Metastatic pancreatic cancer remains one of the most challenging problems facing modern oncology. Most individuals receive this diagnosis only after the illness has reached an advanced phase, making successful treatment more complicated. Once the disease no longer responds to the initial course of therapy, physicians have traditionally had very few reliable therapeutic alternatives available. In 2026, the results of a major international study were published which may change the approach to second-line treatment. Eternity Life Tourism helps patients gain access to state-of-the-art diagnostic and treatment methods at leading clinics abroad, where the latest treatment protocols are already in use.

What the RASolute 302 study revealed

Key data were presented from the international Phase III RASolute 302 trial. A total of 500 individuals with metastatic pancreatic cancer who had already undergone earlier treatment were included in the study. Participants were allocated to treatment with either daraxonrasib or a standard chemotherapy regimen selected by the responsible physician. The study showed that daraxonrasib worked better than standard chemotherapy. People who received this drug lived for a median of 13.2 months, while patients who received regular chemotherapy had a median survival of 6.7 months. A nearly twofold increase in time to disease progression was also observed. At the same time, the risk of death was reduced by approximately 60 per cent, which was one of the best outcomes among second-line therapy trials for this form of the disease. 

Why the choice of treatment remains a pressing issue

When the first treatment stops working, people with advanced pancreatic cancer usually have limited treatment options and poor outcomes. Although conventional cytotoxic treatment may temporarily delay further tumor growth, its clinical benefit is often modest. In addition, treatment-related adverse effects frequently have a negative impact on patients’ everyday functioning and overall well-being. Mutations in the RAS gene, primarily KRAS, are considered the main cause of most pancreatic tumours. Such mutations are found in more than 90 per cent of patients. For a long time, this molecular mechanism was considered virtually inaccessible to drug intervention. The emergence of daraxonrasib has been one of the most significant developments in recent years precisely because the drug targets a broad spectrum of mutations within the RAS family. 

Safety and tolerability of treatment

When comparing the two approaches, it is necessary to evaluate both how well the treatment works and how safely patients can tolerate it. Although serious adverse events were reported in both groups, the need to discontinue treatment completely due to side effects was less frequent with daraxonrasib. The proportion of such cases was around 1%, whereas with standard chemotherapy, treatment was discontinued in more than 11% of patients. The side effects most often reported with daraxonrasib included digestive problems, skin-related reactions, and abnormal laboratory test results. In most cases, these were managed through dose adjustment or symptomatic treatment. This allows many patients to continue treatment without a significant deterioration in their quality of life. 

What is Daraksonrasib?

Daraxonrasib is a new-generation oral targeted therapy, also known as RMC-6236. Its mechanism of action differs from that of conventional KRAS inhibitors. The drug inhibits the active form of RAS proteins regardless of the specific mutation variant, making it potentially suitable for a much larger number of patients. Unlike standard cytotoxic chemotherapy, the drug targets the molecular cause of tumour growth. This approach falls under the category of personalised therapy and requires prior molecular genetic testing of the tumour to confirm the presence of the relevant mutations. 

When daraxonrasib may be the preferred option

The study results do not imply that chemotherapy has become entirely obsolete. It remains a treatment option for patients for whom targeted therapy is unsuitable or unavailable. However, in the presence of relevant molecular alterations, daraxonrasib is now considered a more promising second-line treatment option. Before selecting a course of treatment, a comprehensive assessment of the patient’s condition must be carried out. This takes into account the results of molecular genetic testing, the extent of the tumour, the patient’s general health, previous treatment and any underlying conditions. Only then can it be determined whether the use of the new drug will produce the expected effect.

The introduction of daraxonrasib has been one of the most significant advances in the treatment of previously treated metastatic pancreatic cancer. If you are interested in undergoing molecular diagnostics, obtaining a second opinion from overseas specialists, or arranging treatment using modern anti-cancer drugs, please contact Eternity Life Tourism. The company’s specialists will help you choose a clinic, organise a treatment programme and provide support at every stage of your treatment.

FAQ